Opinion|Videos|June 24, 2024
Differential Diagnosis When Considering Hidradenitis Suppurativa in a Patient
Author(s)Iltefat Hamzavi, MD
A dermatologist provides clinical insights on differential diagnosis strategies when considering hidradenitis suppurativa in patients and the challenges associated with diagnosis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is in your differential diagnosis when considering hidradenitis suppurativa (HS) in a patient and how is this disease definitively diagnosed?
- Average delay in HS diagnosis has been found to be around 10 years. What do you think accounts for this and why is it imperative for patients with HS to be diagnosed sooner?
Advertisement
Related to this article
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
5